ArticleCancer diagnosis & prognosis

Age Is a Risk Factor for Olaparib Dose Modification and Discontinuation in Patients With Ovarian Cancer.

Hiroaki Inui et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.